SREBF2 and urinary bladder cancer: In studies utilizing mRNA/miRNA microarrays and protein analysis in T24 bladder cancer cells, archazolid B was found to activate SREBP2, resulting in severely deregulated cholesterol homeostasis and contributing to archazolid B-induced resistance (Hamm et al., 2014).